Bicarbonate

Bicarbonate

SCHEMBL369397

O=C([O-])[O-].[Ar].[Cs+].[Cs+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL17626746 1.00
Bicarbonate SCHEMBL1930 0.94
Bicarbonate SCHEMBL1697622 0.94 CA4 (0.50)
Bicarbonate SCHEMBL23702350 0.88
Bicarbonate SCHEMBL7520168 0.88
Bicarbonate SCHEMBL14784308 0.88
Bicarbonate SCHEMBL4299405 0.88
Bicarbonate SCHEMBL5535181 0.88 CA4 (0.60)
Bicarbonate SCHEMBL232588 0.88
Bicarbonate SCHEMBL14784307 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347571-B1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. HOFFMANN LA ROCHE (CH) 2026-04-22 EP disclosed
US-12421209-B2 Compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 US disclosed
US-20250276958-A1 COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-09-04 US disclosed
US-20250197370-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-19 US disclosed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 EP disclosed
US-20240279237-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-08-22 US disclosed
US-20240132471-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-04-25 US disclosed
EP-4347571-A1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2024-04-10 EP disclosed
WO-2023066825-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-27 WO disclosed
WO-2022253936-A1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. F. HOFFMANN-LA ROCHE AG (CH) 2022-12-08 WO disclosed
CN-105143209-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2018-03-13 CN disclosed
US-9801961-B2 2-phenylimidazo[1,2-a]pyrimidines as imaging agents HOFFMANN-LA ROCHE INC. (US) 2017-10-31 US disclosed
CN-105229009-B 2-phenylimidazo [1,2-A ] pyrimidines as imaging agents 豪夫迈·罗氏有限公司 2017-09-29 CN disclosed
US-20170128598-A1 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS HOFFMANN-LA ROCHE INC. (US) 2017-05-11 US disclosed
EP-2999701-B1 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS HOFFMANN LA ROCHE (US) 2017-04-12 EP disclosed
WO-2017036978-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS ABBVIE INC. (US) 2017-03-09 WO disclosed
US-20170057966-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS AbbVie Deutschland GmbH & Co. KG (DE) 2017-03-02 US disclosed
CN-106146484-A Quinazoline derivant is as RAF kinase modulator and their method and purposes 埃姆比特生物科学公司 2016-11-23 CN disclosed
EP-2999701-A1 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS Hoffmann-La Roche Inc. (US) 2016-03-30 EP disclosed
US-8097733-B2 Pyrazole derivatives as 5-LO-inhibitors PFIZER INC. (US) 2012-01-17 US disclosed